Evidence map›Paper›PMID 36941691›Full record

ReviewInflammation and regeneration2023

Group 2 innate lymphoid cells and their surrounding environment.

Maiko Naito, Atsushi Kumanogoh

Open access · goldFull text readReview
In one paragraph

Review in Inflammation and regeneration, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Innate Lymphoid Cells Are the Rheostat of Immune Response in the Kidney.Journal of cellular and molecular medicine · 2025
    Review
  7. Article
  8. Dual independent mechanisms underlying gut epithelial remodeling upon sugar substitute consumption.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Maiko NaitoDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. kumanogo@imed3.med.osaka-u.ac.jp.
Japan Agency for Medical Research and Development · JPThe University of Osaka · JP

Funding

Japan Agency for Medical Research and Development (AMED) J200705023Japan Agency for Medical Research and Development (AMED) J200705049Japan Agency for Medical Research and Development (AMED) J200705710Japan Agency for Medical Research and Development (AMED) JP18cm016335Japan Agency for Medical Research and Development (AMED) JP18cm059042Japan Agency for Medical Research and Development - Core Research for Evolutional Science and Technology (AMED-CREST) 22gm1810003h0001Japan Society for the Promotion of Science (JSPS) KAKENHI JP18H05282
6 · The paper itself

Abstract

Since the discovery of group 2 innate lymphoid cells (ILC2s) in 2010, subsequent studies have revealed their developmental pathways, mechanisms of activation and regulation, and immunological roles in tissue homeostasis and tissue-specific diseases in various organs. Although ILC2s are known to express tissue-specific features depending on where they reside, how the surrounding environment affects the functions of ILC2s remains to be fully elucidated. Recent histologic analyses revealed that ILC2s resides in specific perivascular regions in peripheral tissues with their function being controlled by the surrounding cells via cytokines, lipid mediators, neurotransmitters, and cell-cell interactions through surface molecules. This review summarizes the interactions between ILC2s and surrounding cells, including epithelial cells, neurons, immune cells, and mesenchymal cells, with the objective of promoting the development of novel diagnostic and therapeutic methods for ILC2-related diseases.

Indexed as

Adventitial stromal cell (ASC)Group 2 innate lymphoid cell (ILC2)Mesenchymal cellsMicroenvironment

Identifiers

PMID36941691
PMCPMC10026507
OpenAlexW4327971493

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.